Genetic testing for immunotherapies

_________

Oncologica is a leading laboratory in genetic cancer testing.
We help patients and oncologists to get the maximum benefit from new cancer treatments.

What is Immunotherapy?

Are you interested in knowing which DNA tests are most helpful in identifying the most appropriate immunotherapies.

The immune system keeps track of all of the cells and substances normally found in the human body, if there is a foreign invader or abnormal cancer cell that the immune system doesn’t recognize, this raises an alarm, causing the immune system to immediately attack it.

Powerful therapies with high specificity and low toxicity.

Immunotherapy doesn’t work the same for everyone: in some patients it appears to work incredibility well, completely destroying tumours, for other patients, the response can be less dramatic.

Before assessing whether the patient is eligible for these new treatment options it is therefore essential to first identify whether the patient will benefit from from such therapy.

Immunotherapy-highly effetctive
in patients correctly identified
following Immunofocus testing

A comprehensive DNA test to precisely identify patient’s eligible for immunotherapy

Oncologica helps patients and clinicians to expand their treatment options by using precision oncology tests.

Immunofocus PD-L1, MMR and TMB testing can be applied to the routine tumour biopsy to precisely identify patients who can derive benefit from immunotherapy drugs.

THE PROCESS

Immunotherapy
and DNA

The development of cancer is associated with the acquisition of DNA mutations which also results in the expression of mutated proteins on the surface of cancer cells called neoantigens.

Neoantigens are recognised by the body as foreign leading to an attack on the cancer cells by the patient’s own immune cells.

However some cancers prevent this attack by expressing a protein on their surface called PD-L1 which shields the cancer cells from the immune system.

Anti-PD-L1/PD-1 immunotherapy strips this PD-L1 shield away enabling the immune cells to attack the cancer cells.

Limits of
Immunotherapy

Immunotherapy doesn’t work for everyone: in some patients it appears to work incredibility well, completely destroying tumours even after they have begun to spread around the body, but for other patients the response can be less dramatic.

The different responses to immunotherapy reflect differences in the genetic profile and immunoprofile of each cancer patient.

\

In some patients the immune system doesnt recognise the cancer cells as foreign due to lack of neoantigens

\

Tumour Cells with low levels PD-L1 (shielding protein) may not respond to immunotherapy

\

Other genetic characteristics including mismatch repair genes MMR and tumor mutational burden TMB can also affect a good response to immunotheraphy

How can Oncologica’s genomic profiling be helpful for decisions on immunotherapy?

Oncologica now performs a series of genetic and immunoprofiling tests which helps identify those patients most likely to benefit from immunotherapy.

Immunofocus MMR and Immunofocus TMB combined with Oncofocus identify cellular changes such as defects in DNA damage repair and immune signalling that flag up tumours sensitive to immunotherapy. Immunofocus TMB provides an assessment of global DNA mutation burden and asssociated neoantigens.

Patients who score positive in these four tests are strong candidates for immunotherapy.

Oncologica’s testing platforms Immunofocus and Oncofocus enables the precise identification of patients who may benefit from immunotherapy

The immunofocus test can be performed in combination with our most comprehensive test “Oncofocus” that sequences 505 genes capturing 1000s of mutations linked to over 780 targeted therapies and immunotherapies.

Oncologica® is a leading precision oncology certified laboratory based in the prestigious Chesterford Research Park, Cambridge, UK.

Since 2015 we have been helping oncologists and patients every day to get the maximum benefit from new advanced genetic profiling techniques for the treatment of cancer.

A large team of geneticists, pathologists and oncologists for
help patients and treating physicians find a tailor-made cancer therapy through molecular genetics.

Dr Marco Loddo
CO-FOUNDER AND SCIENTIFIC DIRECTOR

BSc PhD
Prof. Gareth H Williams
CO-FOUNDER AND MEDICAL DIRECTOR

BSc, MBChB, PhD, FRCPath, FLSW
Keeda-Marie Hardisty
LEAD CLINICAL SCIENTIST

BSc

Dr Sergio Del Bianco
CLINICAL TEAM – SECOND OPINION

Oncologist

Prof. Giovanni Palazzoni
CLINICAL TEAM – SECOND OPINION

Radiation therapist oncologist

Prof. Umberto Tirelli
CLINICAL TEAM

Oncologist

Dr. Carla Spiga
CLINICAL TEAM – SECOND OPINION

Oncologist

Dr.ssa Eleonora Sanna
CLINICAL TEAM – SECOND OPINION

Oncologist

Dr Alberto Ravaioli
SPECIALIST GENERAL ONCOLOGY

Get a free consultancy on precision oncology

Get in touch with our clinical team to learn about the benefits of precision oncology.

    If you want you can provide further details about the clinical case by replying to the email that our clinical team will send you.

    The information transmitted is used exclusively to process your request. By submitting this form you accept the terms and conditions including our Privacy Policy. At any time you can ask for your personal data to be deleted and removed.

    This form is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    Accept Privacy Policy

    s

    Note to patients: All contents on this page are for informational purposes. Decisions regarding medical treatments and diagnoses must always be made in consultation with your treating clinician.

    More to read and watch
    on precision oncology

    The Business Post

    Oncologica® has developed a DNA test which allows medical professionals select the appropriate precision cancer treatment to defeat tumours.

    The Business Post

    Cambridge News

    Dad with terminal cancer given hope by ground-breaking precision oncology test.

    Cambridge News
    Oncologica® UK ltd.
    Suite 15-16 The Science Village, Chesterford Research Park, Little Chesterford, Cambridge, CB10 1XL
    +44 (0) 1223 785327